Ushbu ishga iqtibos qilgan ishlar

4 ta ish

Ish: CAR-T Cell Performance: How to Improve Their Persistence?

1. Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

   Manh-Cuong Vo, Van-Dinh-Huan Tran, Van‐Tan Nguyen +5

   MaqolaCAR-T cell therapy researchJournal of Hematology & Oncology20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.article.000083

2. Engineering CAR T NK and NKT cell therapies to target cancer stem cells and overcome stem like resistance

   Omer Qutaiba B. Allela, Abdulkareem Shareef, S. Renuka Jyothi +9

   MaqolaCAR-T cell therapy researchDiscover Oncology20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.article.001466

3. Next-generation CAR-T and CAR-NK cell therapies in hematologic malignancies: engineering for persistence, specificity, and safety

   Mutaz Jamal Al-khreisat, Waleed K. Abdulsahib, Ihsan Khudhair Jasim +6

   MaqolaCAR-T cell therapy researchDiscover Oncology20260 iqtibos

   ABIABI:AkademIndex/openalex/2026.article.005310

4. Epigenetic insights and innovations for overcoming barriers in CAR-T cell therapy for cancer

   Viktoria B. Poluektova, Svetlana N. Zuevskaya, Yarmatov Suvon +3

   MaqolaCAR-T cell therapy researchClinical & Translational Oncology20260 iqtibos

   ABIABI:AkademIndex/openalex/2026.article.008555